Immuneering announces clinical supply agreement with Regeneron
Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...
Nasdaq6d
Immuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus Libtayo
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
pharmaphorum6d
Sanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancer
Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...
precisionmedicineonline4d
Immuneering Partners with Regeneron to Study Combined MEK, PD-1 Inhibitor Therapy in Solid Tumors
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
Seeking Alpha28d
Regeneron: Phase III Success In Skin Cancer For Libtayo
LIBTAYO globally grew sales to $288.6M, a +23% YoY growth rate. While DUPIXENT sales grew to $3,817M, a +24% YoY growth rate. Importantly, data in the table below reflect net product sales ...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...